ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

9:00AM-11:00AM: Abstract Number: 1204

Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1052

Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking

(1052–1081) Immunological Complications of Medical Therapy Poster

9:00AM-11:00AM: Abstract Number: 1205

Universal Social Determinants of Health Screening in a Pediatric Rheumatology Specialty Clinic: A Feasibility Study

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1153

Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches

(1124–1154) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 0952

Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21

(0934–0964) Systemic Sclerosis & Related Disorders – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1459

Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual

(1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 1271

Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA)

(1264–1307) RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-11:00AM: Abstract Number: 0916

Upregulation of the M-CSF Receptor on Non-Classical Monocytes from SLE Patients as an Indicator for Premature Monocyte Aging

(0899–0933) SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1111

Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis

(1100–1123) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 0979

Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases

(0965–0992) Epidemiology & Public Health Poster II

9:00AM-11:00AM: Abstract Number: 1006

Use of Implementation Strategies to Promote Adherence of Knee Osteoarthritis Guidelines and Improve Patient Outcomes: A Systematic Review

(0993–1012) Health Services Research Poster II

9:00AM-11:00AM: Abstract Number: 1214

Using Patient Self-Reported Measures to Predict All-Cause Hospitalization in a Population-Based Lupus Cohort

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1213

Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

9:00AM-11:00AM: Abstract Number: 1085

Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

(1082–1099) Measures & Measurement of Healthcare Quality Poster I

9:00AM-11:00AM: Abstract Number: 1203

Vaccination Against SARS-CoV-2 in Inflammatory Arthritis and Factors Determining Its Decision

(1200–1220) Patient Outcomes, Preferences, & Attitudes Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].